(Reuters) -Shares in Wegovy maker Novo Nordisk fell around 4% on Friday to their lowest since August 2021, after U.S.

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

On Friday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported second-quarter adjusted earnings of $12.89 per share, up 12% ...

After the surprise departure of longtime CEO Lars Fruergaard Jørgensen in May, Danish pharma giant Novo Nordisk didn’t take ...

Walt Disney ( DIS) will release its results on Wednesday, with attention on its media networks, theme parks, and streaming services. Analysts expect earnings of $1.47 per share and $23.7bn in revenue, ...

Novo Nordisk, a Danish multinational pharmaceutical company headquartered in Bagsværd with production facilities in nine ...

In May, the Danish pharma said CEO Lars Fruergaard Jørgensen would step down, following a turn in the obesity market. While Novo was the star of the emerging weight loss and diabetes market through ...

Danish leader will face a challenging landscape among competitors ...

Delhi: Global healthcare major Novo Nordisk has announced the appointment of Maziar Mike Doustdar as its new President and ...

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

Novo Nordisk A/S’s best-sellers Ozempic and Wegovy transformed the firm into a global pharmaceutical giant. But four years ...

Shares in Wegovy maker Novo Nordisk fell further on Wednesday as analysts warned of persistent competition from copycat drugs ...